Encompass More Asset Management Purchases 1,128 Shares of Novo Nordisk A/S (NYSE:NVO)

Encompass More Asset Management raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 49.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,397 shares of the company’s stock after acquiring an additional 1,128 shares during the quarter. Encompass More Asset Management’s holdings in Novo Nordisk A/S were worth $292,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Novare Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 3.2% during the 3rd quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock valued at $325,000 after purchasing an additional 85 shares in the last quarter. Rosenberg Matthew Hamilton boosted its holdings in shares of Novo Nordisk A/S by 2.5% during the 3rd quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company’s stock worth $454,000 after buying an additional 94 shares in the last quarter. Burns J W & Co. Inc. NY grew its position in shares of Novo Nordisk A/S by 1.9% during the 3rd quarter. Burns J W & Co. Inc. NY now owns 5,430 shares of the company’s stock worth $647,000 after buying an additional 100 shares during the period. Spinnaker Trust increased its stake in shares of Novo Nordisk A/S by 1.1% in the 3rd quarter. Spinnaker Trust now owns 9,615 shares of the company’s stock valued at $1,145,000 after acquiring an additional 100 shares in the last quarter. Finally, Marco Investment Management LLC lifted its position in shares of Novo Nordisk A/S by 1.5% during the 3rd quarter. Marco Investment Management LLC now owns 6,702 shares of the company’s stock valued at $798,000 after acquiring an additional 100 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have commented on NVO. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Finally, StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Novo Nordisk A/S presently has an average rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $87.94 on Friday. Novo Nordisk A/S has a 52 week low of $78.17 and a 52 week high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The stock has a 50 day moving average price of $95.62 and a two-hundred day moving average price of $115.55. The firm has a market capitalization of $394.65 billion, a P/E ratio of 28.46, a P/E/G ratio of 0.90 and a beta of 0.45.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.